Table 4 The upper part (lite blue) summarizes the minor vascular complications of the total population and of the two groups. The parentheses list the number of minor vascular complications and the number of patients available for analysis. No significant difference was observed between the two groups with respect to minor vascular complications
|  | Total population (n = 257) | SR-group(n = 148) | AF-group (n = 109) | p Value | OR (95% CI) |
|---|---|---|---|---|---|
Follow-up Minor vascular complication | |||||
 30 days | 22.6% (58/257) | 22.3% (33/148) | 22.9% (25/109) | 1.00 | 1.09 (0.61–1.96) |
 3 months | 23.0% (59/257) | 22.3% (33/148) | 23.9% (26/109) | 0.767 | 1.09 (0.61–1.96) |
 6 months | 24.8% (60/241) | 23.9% (33/137) | 26.0% (27/104) | 0.764 | 1.12 (0.62–2.01) |
 12 months | 27.3% (60/219) | 26.4% (33/124) | 28.4% (27/95) | 0.762 | 1.11 (0.61–2.01) |
Follow-up Major bleeding | |||||
 30 days | 3.5% (9/257) | 4.1% (6/148) | 2.8% (3/109) | 0.737 | 0.67 (0.16–2.74) |
 3 months | 3.9% (10/257) | 4.7% (7/148) | 2.8% (3/109) | 0.525 | 0.57 (0.14–2.26) |
 6 months | 4.5% (11/241) | 5.8% (8/137) | 2.9% (3/104) | 0.360 | 0.48 (1.13–1.87) |
 12 months | 5.5% (12/219) | 7.2% (9/124) | 3.2% (3/95) | 0.240 | 0.42 (0.11–1.60) |
Follow-up Minor bleeding | |||||
 30 days | 19.8% (51/257) | 21.6% (32/148) | 17.4% (19/109) | 1.00 | 1.09 (0.61–1.96) |
 3 months | 19.8% (51/257) | 21.6% (32/148) | 17.4% (19/109) | 0.767 | 1.09 (0.61–1.96) |
 6 months | 21.0% (51/241) | 23.0% (32/137) | 18.3% (19/104) | 0.764 | 1.12 (0.62–2.01) |
 12 months | 23.1% (51/219) | 25.4% (32/124) | 20.0% (19/95) | 0.762 | 1.11 (0.61–2.01) |